Clinical trial · Observational
Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells
Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells in Patients With Advanced or Metastatic Tumors.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study investigates the ability of heat shock protein HSP70 to isolate and quantify circulating tumor cells (CTCs) in patients with advanced or metastatic tumors. CTCs will be isolated from peripheral blood before antineoplastic treatment and again after three months. Isolation using HSP70 will be compared with standard CTC isolation by EpCAM. Additionally, imaging parameters of the primary tumor (if available) and metastases will be analysed and correlations between molecular alterations and imaging parameters will be assesed.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Stage IV | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
| Melanoma Stage IV | Melanoma | CURATED_BROADER | 0.78 |
| Pancreatic Cancer Stage IV | Malignant Pancreatic Neoplasm | CURATED_BROADER | 0.78 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
| Squamous Cell Carcinoma | Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CTC isolation by HSP70 | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- HSP70CTC
- description
- Isolation of circulating tumor cells by HSP70
- interventionNames
- Diagnostic Test: CTC isolation by HSP70
Primary outcomes (1)
- measure
- Radiographic response to initial treatment
- timeFrame
- 3 months after study enrollment
- description
- radiographic response to treatment will be scored according to RECIST criteria and associated with the number of CTC
Secondary outcomes (4)
- measure
- Correlation between number of CTC isolated with HSP70 compared to EpCAM
- timeFrame
- 3 months (at both CTC assessment timepoints)
- description
- the number of CTCs obtained by the novel HSP70 method will be compared to the current gold standard that uses EpCAM. This will be performed for the whole cohort and separate for each tumor site
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Metastatic malignant melanoma (stage IV) * Metastatic or unresectable pancreatic adenocarcinoma (stage III or IV) * Metastatic breast cancer * Metastatic sarcoma * Metastatic squamous cell carcinoma of the cervix uteri, head and neck region, vulva, anus or penis * hormone-refractory prostate cancer Exclusion Criteria: * psychiatric disorders that impede adequate informed consent
References
Publications (1)
- DERIVEDRoy AA, Pandey A, Dhas N, Hegde MM, Parekh HS, Andugulapati SB, Nandakumar K, Satish Rao BS, Mutalik S. The Confluence of Nanotechnology and Heat Shock Protein 70 in Pioneering Glioblastoma Multiforme Therapy: Forging Pathways Towards Precision Targeting and Transformation. Adv Pharmacol Pharm Sci. 2025 Apr 24;2025:1847197. doi: 10.1155/adpp/1847197. eCollection 2025. PMID 40313865